Owing to a production error, several dependent variables were omitted from the part of Table 2 that pertains to Study 1 in the article as originally published. The variables in question are mean diastolic blood pressure, breath rate, C-reactive protein concentration, D-dimer concentration, fasting glucose concentration and plasma potassium concentration. The complete part of Table 2 that pertains to Study 1 is presented here.
Table 2
| Dependent variable | Treatment group  | Mean baseline | Mean T1 | p-value of comparison baseline vs T1 | p-value of T1 comparison of Group II vs Group I |
|---|---|---|---|---|---|
| Loss of smell/taste, n | I | 33 (82.5) | 30 (75) | NS | <0.05 |
| II | 34 (85) | 19 (47.5) | <0.05 | ||
| Dyspnea, n | I | 30 (75) | 10 (25) | <0.001 | NS |
| II | 28 (70) | 8 (20) | <0.001 | ||
| Dry cough, n | I | 36 (90) | 18 (45) | <0.001 | NS |
| II | 32 (80) | 12 (30) | <0.001 | ||
| Fever, n | I | 38 (95) | 10 (25) | <0.001 | NS |
| II | 37 (92.5) | 4 (10) | <0.001 | ||
| Need for oxygen, n | I | 22 (55) | 7 (17.5) | NS | NS |
| II | 18 (45) | 5 (12.5) | NS | ||
| BP syst., mm Hg | I | 130.6 ± 10.5 | 165.1 ± 12.1 | <0.05 | <0.05 |
| II | 137.5 ± 22.5 | 128.3 ± 12.0 | NS | ||
| BP diast., mm Hg | I | 86.0 ± 8.6 | 89.0 ± 10.6 | NS | NS |
| II | 85.25 ± 12.4 | 81.1 ± 6.7 | NS | ||
| Breath rate/min | I | 24.8 ± 4.6 | 18.4 ± 3.1 | NS | NS |
| II | 24.2 ± 3.1 | 16.2 ± 1.8 | <0.05 | ||
| CRP, mg/l | I | 72.4 ± 16.7 | 28.1 ± 12.9 | <0.05 | NS |
| II | 65.8 ± 17.9 | 17.1 ± 8.7 | <0.05 | ||
| D-dimer, ng/ml | I | 736.7 ± 112.6 | 574.8 ± 106.4 | NS | <0.05 |
| II | 755.5 ± 106.1 | 357.3 ± 71.1 | <0.001 | ||
| Fasting glucose, mmol/l | I | 5.9 ± 1.5 | 12.69 ± 1.31 | <0.05 | <0.05 |
| II | 6.9 ± 2.2 | 8.44 ± 1.60 | NS | ||
| [K+] plasma, mmol/l | I | 4.36 ± 0.32 | 4.28 ± 0.50 | NS | NS |
| II | 4.22 ± 0.40 | 4.43 ± 0.45 | NS |
Study 1. Repeated measures analysis comparing changes in variables from baseline to 5 days treatment (T1).
SD, standard deviation; mean BP, mean blood pressure; [K+] plasma, plasma concentration of potassium; CRP, C-reactive protein. Figures are expressed as Mean and Standard Deviation. NS, non-significant difference. No patient required ventilation: patients with oxygen saturation less than 92% given oxygen by mask.
The publisher apologizes for this error. The original article has been updated.
Summary
Keywords
COVID-19, mineralocorticoid receptor, spironolactone and dexamethasone, ATP - adenosine triphosphate, anosmia and ageusia
Citation
Frontiers Production Office (2021) Erratum: Follow Your Nose: A Key Clue to Understanding and Treating COVID-19. Front. Endocrinol. 12:830164. doi: 10.3389/fendo.2021.830164
Received
06 December 2021
Accepted
06 December 2021
Published
16 December 2021
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
12 - 2021
Updates
Copyright
© 2021 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Cellular Endocrinology, a section of the journal Frontiers in Endocrinology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.